Vnitr Lek 2025, 71(4):249-254 | DOI: 10.36290/vnl.2025.045

Atherosclerosis progression under the influence of subclinical inflammation

Eva Tůmová
Metabolická JIP IKEM, Praha

Long-term subclinical inflammation is one of the factors that influence the progression of atherosclerosis and lead to the destabilization of atherosclerotic plaques with increased risk of complications such as acute coronary syndrome. Control of the pro-inflammatory state brings similar benefits as pharmacological management of traditional risk factors of atherosclerosis resulting in lower risk of cardiovascular events. Decreased inflammatory state can be monitored, for example, by the concentration of highly sensitive C-reactive protein. The possibilities of targeted influence of subclinical inflammation are currently limited, but it is possible to use available substances with hypolipidemic effect, which are able to decrease the pro-inflammatory state resulting in a further reduction of cardiovascular risk.

Keywords: atherosclerosis, subclinical inflammation, hs-CRP, statins.

Accepted: June 3, 2025; Published: June 19, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tůmová E. Atherosclerosis progression under the influence of subclinical inflammation. Vnitr Lek. 2025;71(4):249-254. doi: 10.36290/vnl.2025.045.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26. doi: 10.1056/NEJM199901143400207. PMID: 9887164. Go to original source... Go to PubMed...
    2. Kong P, Cui ZY, Huang XF, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022 Apr 22;7(1):131. doi: 10.1038/s41392-022-00955-7. PMID: 35459215; PMCID: PMC9033871. Go to original source... Go to PubMed...
    3. Held C, White HD, Stewart RAH, et al.; STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077. PMID: 29066452; PMCID: PMC5721818. Go to original source... Go to PubMed...
    4. Emerging Risk Factors Collaboration; Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012 Oct 4;367(14):1310-20. doi: 10.1056/NEJMoa1107477. PMID: 23034020; PMCID: PMC3714101. Go to original source... Go to PubMed...
    5. Badimon L, Peña E, Arderiu G, et al. C-Reactive Protein in Atherothrombosis and Angiogenesis. Front Immunol. 2018 Mar 2;9:430. doi: 10.3389/fimmu.2018.00430. PMID: 29552019; PMCID: PMC5840191. Go to original source... Go to PubMed...
    6. Bjelakovic G, Nikolova D, Gluud C. Antioxidant supplements to prevent mortality. JAMA. 2013 Sep 18;310(11):1178-9. doi: 10.1001/jama.2013.277028. PMID: 24045742. Go to original source... Go to PubMed...
    7. Tardif JC, et al; Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 May 24;371(9626):1761-8. doi: 10.1016/S0140-6736(08)60763-1. PMID: 18502300. Go to original source... Go to PubMed...
    8. STABILITY Investigators; Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30. PMID: 24678955. Go to original source... Go to PubMed...
    9. Ridker PM, Everett BM, Pradhan A, et al. CIRT Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 Feb 21;380(8):752-762. doi: 10.1056/NEJMoa1809798. Epub 2018 Nov 10. PMID: 30415610; PMCID: PMC6587584. Go to original source... Go to PubMed...
    10. Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. doi: 10.1016/j.jacc.2012. 10. 027. Epub 2012 Dec 19. PMID: 23265346. Go to original source...
    11. Vaidya K, Arnott C, Martínez GJ, et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 2):305-316. doi: 10.1016/j.jcmg.2017. 08. 013. Epub 2017 Oct 18. PMID: 29055633. Go to original source...
    12. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468. doi: 10.1093/eurheartj/ehac458. PMID: 34458905. Go to original source... Go to PubMed...
    13. Ridker PM, MacFadyen JG, Everett BM, et al. CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018 Jan 27;391(10118):319-328. doi: 10.1016/S0140-6736(17)32814-3. Epub 2017 Nov 13. PMID: 29146124. Go to original source... Go to PubMed...
    14. Ruscica M, Ferri N, Macchi C, et al. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes? Ann Med. 2018 Sep;50(6):461-484. doi: 10.1080/07853890.2018.1498118. Epub 2018 Oct 15. PMID: 29976096. Go to original source... Go to PubMed...
    15. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007 May 22;49(20):2003-9. doi: 10.1016/j.jacc.2007. 01. 083. Epub 2007 May 4. PMID: 17512355. Go to original source...
    16. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998 Sep 1;98(9):839-44. doi: 10.1161/01.cir.98. 9. 839. PMID: 9738637. Go to original source...
    17. Clearfield M. C-reactive protein levels and outcomes after statin therapy. Curr Atheroscler Rep. 2006 Jan;8(1):8-9. PMID: 16455006. Go to original source... Go to PubMed...
    18. P M Burger, J A N Dorresteijn, S Koudstaal, et al. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 59 trials, European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.2515, https://doi.org/10.1093/eurheartj/ehad655.2515 Go to original source...
    19. Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019 Oct 8;322(14):1381-1391. doi: 10.1001/jama.2019.14120. PMID: 31475726; PMCID: PMC6724415. Go to original source... Go to PubMed...
    20. Wilkins JT, Ning H, Berry J, et al. Lifetime Risk and Years Lived Free of Total Cardiovascular Disease. JAMA. 2012;308(17):1795-1801. doi:10.1001/jama.2012.14312 Go to original source... Go to PubMed...
    21. Cicero AFG, Fogacci F, Rizzoli E, et al. Brisighella Heart Study Group. Correction: Cicero et al. Long-Term Impact of Different Triple Combination Antihypertensive Medications on Blood Pressure Control, Metabolic Pattern and Incident Events: Data from the Brisighella Heart Study. J. Clin. Med. 2021, 10, 5921. J Clin Med. 2022 Nov 30;11(23):7109. doi: 10.3390/jcm11237109. Erratum for: J Clin Med. 2021 Dec 17;10(24):5921. doi: 10.3390/jcm10245921. PMID: 36498826; PMCID: PMC9737114. Go to original source...
    22. Madej A, Dąbek J, Majewski M, et al. Effect of perindopril and bisoprolol on IL-2, INF-γ, hs-CRP and T-cell stimulation and correlations with blood pressure in mild and moderate hypertension. Int J Clin Pharmacol Ther. 2018 Sep;56(9):393-399. doi: 10.5414/CP203249. PMID: 29809132. Go to original source... Go to PubMed...
    23. Awad K, Zaki MM, Mohammed M, Let al. Lipid and Blood Pressure Meta-analysis Collaboration Group. Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Mayo Clin Proc. 2022 Oct;97(10):1808-1823. doi: 10.1016/j.mayocp.2022. 06. 036. PMID: 36202494. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.